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Abstract
Backgrounds: Conventional in vitro approach using human ether-a-go-go related gene (hERG) assay has been
considered worldwide as the first screening assay for cardiac repolarization safety. However, it does not always
oredict the potential QT prolongation risk or pro-arrhythmic risk correctly. For adaptable preclinical strategiesto
evaluate global cardiac safety, an on-chip quasi-in vivo cardiac toxicity assay for lethal arrhythmia (ventricular
tachyarrhythmia) measurement using ring-shaped closed circuit microelectrode chip has been developed.
Results: The ventricular electrocardiogram (ECG)-like field potential data, which includes both the repolarization
and the conductance abnormality, was acquired from the self-convolutied extracellular field potentials (FPs) of a
lined-up cardiomyocyte network on a circle-shaped microelectrode in an agarose microchamber. When Astemisol
applied to the closed-loop cardiomyocyte network, self-convoluted FP profile of normal beating changed into an
early afterdepolarization (EAD) like waveform, and then showed ventricular tachyarrhythmias and ventricular
fibrilations (VT/Vf). QT-prolongation-like self-convoluted FP duration prolongation and its fluctuation increase was
also observed according to the increase of Astemizole concentration.
Conclusions: The results indicate that the convoluted FPs of the quasi-in vivo cell network assay includes both of
the repolarization data and the conductance abnormality of cardiomyocyte networks has the strong potential to
prediction lethal arrhythmia.
Findings
Lethal arrhythmia has been one of the major safety con-
cerns for the pharmaceutical industry in selecting and
developing compounds. Hence, effects of compounds on
the cardiovascular system like blood pressure, heart rate,
and electrocardiogram should be assessed appropriately
[1,2]. Integrated assay systems using human ether-a-go-
go related gene (hERG)-transfected HEK-293/CHO-cells
(hERG assay), isolated animal tissues (APD or MAPD
assay) and conscious and/or anesthetized whole animals
(QT or MAPD assay), are currently used to identify QT
prolongation [3-5]. Those assay systems are useful to
predict QT prolongation risk (inhibition of repolariza-
tion process) and conductance’s abnormalities. However,
they cannot fully predict the potential pro-arrhythmic
activities such as Torsades de Pointes (TdP), ventricular
tachycardia (VT) or ventricular fibrillation (Vf) induced
by compounds [6-8]. In this context, there is a long-
standing and urgent need for a surrogate marker that
can distinguish the torsadogenic potential from the QT
interval duration.
We here propose a quasi-in vivo cardiac toxicity assay,
which is a new in-vitro cell network assay technology plat-
form where on-chip technology is used as an assay tool to
bridge the gap between conventional in vitro single-cell-
based studies and in vivo human clinical settings in terms
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any medium, provided the original work is properly cited.of cardiac toxicity of new chemical entities for drug devel-
opment. Potential advantages of the proposed strategy of
our quasi-in vivo assay to predict lethal arrhythmia (TdP/
VT/Vf) by evaluation of spatial cell-to-cell conductance
fluctuation using the on-chip cell network loop which can
choose different conductance pathways of human cardio-
myocytes among neighboring circulations. We have
shown that the on-chip cell network loop model would
offer the novel platform to assess the proarrhythmic (not
only TdP but also VT/Vf) risks of compounds.
Figure 1 shows the principle and the system set-up of
the on-chip quasi-in vivo cell network measurement
system. Figure 1(a) shows the relationship of electrophy-
siological profiles of the single cardiomyocyte extracellu-
lar field potential (FP) profile (A), the convoluted FP
profiles of lined-up cardiomyocyte network (B), and the
surface electrocardiogram (ECG) of individuals (i.e., in
vivo surface ECG) (C). The surface ECG is a transthor-
acic electrical signal of the heart muscle depolarizes dur-
ing each heart beat externally recorded by skin
electrodes. A typical ECG tracing of the cardiac cycle
(heartbeat) consists of a P wave, a QRS complex, and a
T wave. ST interval in quasi-ECG model is considered
to correspond the duration of S wave to the apex of T
Figure 1 On-chip quasi-in vivo cardiac toxicity measurement assay fabrication. (a) Relationship of field potential profile (FP) of single
cardiomyocyte (A), quasi -in vivo ECG signals convoluted from FP profiles of lined-up cardiomyocyte network (B), and the surface
electrocardiogram (ECG) of individuals (C). (b) System set-up. (c) Fabrication procedure of closed circuit-shaped lined-up cardiomyocyte network.
(d) Crossectional view of loop electrode chip. (e) Phase-contrast image of the ring-shaped closed circuit electrodes. Bar, 1 mm.
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Page 2 of 5Figure 2 Abnormal beating and fibrillation caused by arrhythmia compound (Astemizole) in a circuit-type mouse embryonic
cardiomyocyte network. (a) Procedure of compound application. (b) time course FP (quasi-in vivo ECG of ST interval) profiles after addition of
1 μM Astemizole, (c) Astemizole concentration dependence of FP waveform change. (d)-(f) Astemizole concentration dependence of FP
waveform change in beating frequency (d), ST (e), and short-term variability (STV) of ST (f) in three different ring shape electrodes of 1 mm in
diameter. *: p < 0.05, **: p < 0.01, ***: P < 0.005, compareed to control in paired t-test.
Table 1 Parameter of field potential recordings of cardiomyocytes circuit on ring-type electrodes at the administration
of Astemizole
Sample Beating frequency ST
Mean ± SD (Hz) Mean ± SD (ms) STV (ms)
Before 10 nM 100 nM 1 μM
† Before 10 nM 100 nM 1 μM
† Before 10 nM 100 nM 1 μM
†
1 0.53 ± 0.04 0.47 ± 0.06 0.54 ± 0.06 0.29 ± 0.09
a 408 ± 10 427 ± 9 509 ± 23 446 ± 12 7.8 6.1 4.6 9.2
2 0.5 ± 0.05 0.45 ± 0.05 0.47 ± 0.05 0.68 ± 0.26
a 403 ± 5 425 ± 7 481 ± 12 473 ± 49 3.4 3.1 3.3 16.9
3 0.63 ± 0.09 0.54 ± 0.05 0.52 ± 0.08 0.47 ± 0.13
a 364 ± 6 386 ± 5 420 ± 7 441 ± 27 3.0 2.7 3.6 7.7
4 0.65 ± 0.06 0.59 ± 0.05 0.56 ± 0.05 0.41 ± 0.09
a 445 ± 9 491 ± 14 580 ± 27 423 ± 26 2.9 3.5 4.6 21.7
5 0.54 ± 0.11 0.38 ± 0.1 0.36 ± 0.06 0.28 ± 0.12
b 311 ± 6 337 ± 4 356 ± 4 410 ± 36 1.9 1.7 2.2 5.9
6 0.58 ± 0.06 0.52 ± 0.04 0.52 ± 0.06 0.58 ± 0.22
a 425 ± 7 455 ± 10 497 ± 7 526 ± 19 3.6 3.6 4.0 11.0
7 0.53 ± 0.04 0.47 ± 0.06 0.54 ± 0.06 0.29 ± 0.09
a 371 ± 8 402 ± 6 428 ± 4 435 ± 54 3.0 3.0 2.6 17.1
Mean 0.57 0.49 0.50 0.48 390 418 467 451 3.7 3.4 3.5 12.8
SD 0.05 0.07 0.07 0.16 45 49 73 38 1.9 1.3 0.9 5.8
t-tset *** * *** *** ** **
a: Fibrillation after abnormal beating, b: Abnormal beating, †: Calculation from FP recordings just before abnormal beating.
*: p < 0.05, **: p < 0.01, ***: P < 0.005, compareed to control in paired t-test.
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gating FP signals in lined-up ventricles cardiomyocyte
cell network (B) should represent the characteristics of a
piece of ventricles tissue, i.e., quasi-in vivo ECG signals
in ventriucles (ST interval).
As shown in Figure 1(b), the agarose microchamber
fabrication system (AMCF) was used for quasi-in vivo
preclinical cardiac toxicity assay, in which extracellular
signals (FP) of cardiomyocyte cells in geometrically pat-
terning chambers have been recorded with an multielec-
trode array (MEA) system [9-13]. For the on-chip quasi-
in vivo measurement of quasi-in vivo ECG signals, a
closed circuit-shaped lined-up cardiomyocyte network
was cultivated in a closed circuit-shaped agarose micro-
chamber fitting to the closed loop single electrode,
which was fabricated by a spot-heating of a portion of
agarose layer as follows (Figure 1(c)): The chip was first
coated with collagen Type I-C (Nitta gelatin), and then
were spin-coated with 2% (w/v) agarose (GenePure Low-
Melt ISC BioExpress) at 1500 rpm for 20 s. To form the
closed circuit chamber for the ring-shaped cell network
model, a portion of agarose gel layer on the surface of
MEA was removed by the spot heating of focused 1480
nm infrared laser. Figure 1(d) also shows the cross-sec-
tional schematic drawing of the spatial arrangement of
cardiomyocytes in a closed loop-shaped indium tin
oxide (ITO) electrode in the quasi-in vivo chip.
Cardiomyocytes were isolated from 13-day-old mouse
embryos (ICR) and were placed in agarose micro-cham-
ber on the MEA chip with a concentration having 5 ×10
5 cells/ml (more than 73.6% purity of beating cardio-
myocytes), and cultivated in a cell culture medium (Invi-
trogen DMEM supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 mg/mL streptomy-
cin) at 37°C with a humidified atmosphere of 95% air
and 5% CO2. The attached cells on the collagen layer in
the agarose micorochamber grew and extended to form
the electrophysiologically connected cardiomyocyte
within 7 days (Figure 1(e)).
Figure 2 shows the results of quasi-in vivo ECG sig-
nals acquired from the closed loop-shaped circuits. To
evaluate the prediction ability of ventricular lethal
arrhythmia using this cell network assay, Astemizole,
which is one of the false-negative compounds on APD
prolongation in guinear-pig papillary muscle assay, was
applied to the cardiomyocyte networks for VT/Vf mea-
surement with the procedures as shown in Figure 2(a).
In Figure 2(b), the time course of FP (quasi-in vivo
ECG) waveform changed from a normal beating to an
early afterdepolarization (EAD) like waveform, which
maintains their beating intervals with abnormal addi-
tional depolarization during phase 2 or phase 3 of the
cardiac action potential before normal repolarization is
competed, and then changed into VT/Vf about 3 min
after 1 μM Astemizole application. It should be noted
that the EAD and ST interval prolongation started
simultaneously in this example. Figure 2(c) shows the
example of the FP (quasi-in vivo ECG) waveform of
ring-shaped cardiomyocyte network in the short closed
loop electrodes (1 mm in diameter) and we confirmed
that the length of ST interval apparently prolonged and
the fluctuation (short-term variability: STV [14]) of ST
duration increased according to the increase of Astemi-
zole concentration.
Figures 2(d) to 2(f), and Table 1 show the summaries
of the ring-shaped circuits (1 mm in diameter), indicat-
ing beating frequencies (d), ST (e), and STV of ST (f).
A ss h o w ni nt h ea b o v ed a t a ,t h ea c q u i r e ds i g n a l s
showed ST prolongation and STV increase independent
to the circuit diameter differences and similar to the
surface ECG signals, but also the occurrence of EAD or
subsequent VT/Vf like waveforms, which is similar to
the results of in vivo QT screening [15].
There are several advantages of this ring-shaped cell
network: First, the round shape is more strong and
stable to maintain their spatial cell network arrange-
ments than the linearly lined-up cardiomyocyte network.
For example, when we cultivate cardiomyocytes in the
linearly lined-up network, the cardiomyocytes at the
both ends of linearly lined-up cell network was easily
shrunk to the center during their beating because of
their force generation and detachment from substrate.
Next, as there is no end of cell network in closed loop
design, there is no need to arrange pacemaker cardio-
myocytes to particular points such as the end of cell
network in lined-up model. Third and finally, there is a
potential to become a virtual re-entry model, in which
the generation of irregular propagation of excitable con-
duction should be enhanced during its circulation.
The above results also shows the potential of the next
generation of on-chip in vitro screening assay using cell
network measurements of repolarization and conduc-
tance abnormalities for the estimation of delayed repo-
larization-associated ventricular tachyarrhythmia (e.g.,
Torsade de Pointes, VT, Vf), which could not be
acquired from the in vivo assay such as hERG and APD
measurements.
A simple quasi-in vivo ECG measurement assay using
closed loop electrode cardiomyocyte network has been
developed and the results showed the typical arrhythmia
profiles, in which both the temporal repolarization infor-
mation and the spatial beating propagation information
appeared.
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